To evaluate appropriateness of enoxaparin bioavailability at two different sites of subcutaneous administration (arms or abdomen) in primary or secondary prevention of thromboembolism in a population of patients with severe obesity
BMI >40 kg/m2
indication to primary or secondary thromboprophylaxis (Padua Score > 4), as clinical practice
creatinine clearance <30 mL/min (based on Cockcroft-Gault equation using adjusted body weight),
pregnant women,
low platelet count (<50.000/microL or <100.000/microL plus additional risk factors for bleeding),
active bleeding,
Prospective observational study, multicentric. Target population: Patients with BMI 40 kg/m2 hospitalized, candidates for anticoagulation therapy in prophylaxis (PADUA score 4).
Cohort
Prospective
Not listed
The primary outcome is the achievement of both target anti-factor Xa levels at peak, defined as 0.2 to 0.4 IU/mL, and at trough, defined as >0.1 IU/mL.
To evaluate appropriateness of enoxaparin bioavailability at two different sites of subcutaneous administration (arms or abdomen) in primary or secondary prevention of thromboembolism in a population of patients with severe obesity
Click on the lead sponsor to view all of their trials.
This trial is not recruiting at the moment. You can still explore other options:
